Autolus Therapeutics (AUTL) & The Competition Head-To-Head Survey

Autolus Therapeutics (NASDAQ: AUTL) is one of 114 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its rivals? We will compare Autolus Therapeutics to similar businesses based on the strength of its profitability, dividends, risk, analyst recommendations, earnings, valuation and institutional ownership.

Profitability

This table compares Autolus Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Autolus Therapeutics N/A N/A N/A
Autolus Therapeutics Competitors -5,144.22% -64.24% -27.96%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Autolus Therapeutics and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Autolus Therapeutics 0 1 4 0 2.80
Autolus Therapeutics Competitors 834 2774 6059 261 2.58

Autolus Therapeutics presently has a consensus price target of $44.00, suggesting a potential upside of 57.14%. As a group, “Biological products, except diagnostic” companies have a potential upside of 33.52%. Given Autolus Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Autolus Therapeutics is more favorable than its rivals.

Earnings & Valuation

This table compares Autolus Therapeutics and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Autolus Therapeutics $1.41 million -$44.75 million -19.72
Autolus Therapeutics Competitors $897.63 million $190.37 million -1.33

Autolus Therapeutics’ rivals have higher revenue and earnings than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

40.6% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 15.7% of shares of all “Biological products, except diagnostic” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

About Autolus Therapeutics

Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma. It is also developing AUTO4, a programmed T cell therapy that is in Phase I/II clinical trial for the treatment of peripheral T-cell lymphoma; and AUTO6, a programmed T cell therapy for treating neuroblastoma. Autolus Therapeutics plc has a collaboration partnership with AbCellera Biologics Inc. on antibody discovery project. The company was founded in 2014 and is headquartered in London, the United Kingdom.

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.